NEOG (Neogen) Debt-to-Revenue : 0.94 (As of May. 2024)

View and export this data going back to 1989. Start your Free Trial

What is Neogen Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Neogen's Short-Term Debt & Capital Lease Obligation for the quarter that ended in May. 2024 was $2.4 Mil. Neogen's Long-Term Debt & Capital Lease Obligation for the quarter that ended in May. 2024 was $888.4 Mil. Neogen's annualized Revenue for the quarter that ended in May. 2024 was $947.2 Mil. Neogen's annualized Debt-to-Revenue for the quarter that ended in May. 2024 was 0.94.

Neogen Debt-to-Revenue Historical Data

The historical data trend for Neogen's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neogen Debt-to-Revenue Chart

Neogen Annual Data

Trend

May15

May16

May17

May18

May19

May20

May21

May22

May23

May24

Debt-to-Revenue

Get a 7-Day Free Trial

1.08

0.96

Neogen Quarterly Data
	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24
Debt-to-Revenue	Get a 7-Day Free Trial															0.92	0.97	0.97	0.97	0.94

Competitive Comparison of Neogen's Debt-to-Revenue

For the Diagnostics & Research subindustry, Neogen's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neogen's Debt-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Neogen's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Neogen's Debt-to-Revenue falls into.

Neogen Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Neogen's Debt-to-Revenue for the fiscal year that ended in May. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(2.447	+	888.391)	/	924.222
	=	0.96

Neogen's annualized Debt-to-Revenue for the quarter that ended in May. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(2.447	+	888.391)	/	947.176
	=	0.94

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (May. 2024) Revenue data.

Neogen Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Neogen's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Neogen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Neogen Corp (NAS:NEOG) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

NG2:Germany

Address

620 Lesher Place, Lansing, MI, USA, 48912

Website

https://www.neogen.com

Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, Neogen performs diagnostics to detect unintended substances in food and animal feed, such as pathogens, allergens, and drug residues, for food and feed processing companies. In animal safety, Neogen sells veterinary instruments, pharmaceuticals, disinfectants, and genomics tests for animals, including cattle, horses, and canines. Sales in the United States account for maximum revenue, and it also has its presence in United Kingdom and other countries.

Executives

James P Tobin	director	620 LESHER PLACE, LANSING MI 48895
Douglas Edward Jones	officer: Vice President, CCO	620 LESHER PLACE, LANSING MI 48912
James C Borel	director	1007 MARKET STREET, WILMINGTON DE 19898
David H. Naemura	officer: VP & CFO	C/O GATES INDUSTRIAL CORPORATION PLC, 1144 FIFTEENTH STREET, SUITE 1400, DENVER CO 80202
John Edward Adent	officer: Chief Executive Officer	822 7TH STREET, SUITE 740, GREELEY CO 80631
William T Boehm	director
Jason Warren Lilly	officer: Vice President	620 LESHER PLACE, LANSING MI 48912
Amy M Rocklin	officer: Chief Legal & Reg. Officer	620 LESHER PLACE, LANSING MI 48912
Steven J. Quinlan	officer: VP & CFO	620 LESHER PLACE, LANSING MI 48912
Jeffrey D Capello	director	C/O NEOGEN CORP., 620 LESHER PLACE, LANSING MI 48912
Aashima Gupta	director	C/O NEOGEN CORPORATION, 620 LESHER PLACE, LANSING MI 48912
Darci L Vetter	director	620 LESHER PLACE, LANSING MI 48912
Ronald D Green	director	620 LESHER PLACE, LANSING MI 48912
Terri A Morrical	officer: General Manager
G Bruce Papesh	director	726 APPLEGATE LANE, EAST LANSING MI 48823